Shuttle Pharmaceuticals (Nasdaq: SHPH) announced a non-binding letter of intent dated Oct 9, 2025 to acquire AI developer Molecule.ai for a $10 million purchase price payable at closing subject to milestones.
Molecule.ai provides an AI drug-discovery platform using LLMs with modules for molecule property prediction, drug-target interaction modeling, and an initial Agentic AI mode to automate multi-step discovery workflows. Shuttle will acquire all rights and assume liabilities; Molecule.ai will extend the platform and assist hiring. Consideration will be a mix of cash and Shuttle common shares tied to milestone completion.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.